- $1.75m
- $0.74m
- $24.16m
- 40
- 75
- 29
- 46
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.58 | ||
Price to Tang. Book | 5.43 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.08 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -302.48% | ||
Return on Equity | -162.95% | ||
Operating Margin | -87.75% |
Financial Summary
Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 23.65 | 41.88 | 44.48 | 35.4 | 24.16 | 19.73 | 21.58 | 120.91% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
cbdMD, Inc. produces and distributes cannabidiol (CBD) products. The Company owns and operates CBD brands cbdMD, Paw CBD and cbdMD Botanicals. Its cbdMD brand of products includes a range of premium every day and functional CBD products, including tinctures; gummies; topicals; capsules; drink mixes; and sleep, focus and calming aids.Its Paw CBD brand of products includes a line of veterinarian-formulated products including tinctures, chews, topicals products in varying strengths and formulas. Its cbdMD Botanicals brand of beauty and skincare products features facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care stock-keeping units (SKU). cbdMD, Paw CBD and cbdMD Botanicals products are distributed through its e-commerce websites, third party ecommerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers. Its products are sold through www.cbdmd.com, www.pawcbd.com, and cbdmdbotanicals.com Websites.
Directors
- Martin Sumichrast CHM (55)
- Raymond Coffman CCE (60)
- T. Ronan Kennedy CFO (43)
- Francisco Mangual SVP (43)
- David Johnson SVP (52)
- Matthew Coapman CMO (46)
- Sibyl Swift VPR (41)
- Lance Blundell GCN (51)
- Peter Ghiloni IND (71)
- William Raines IND (62)
- Bakari Sellers IND (37)
- Scott Stephen IND (56)
- Last Annual
- September 30th, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 17th, 2015
- Public Since
- November 17th, 2017
- No. of Employees
- 52
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 3,763,433
- Address
- 8845 Red Oak Blvd, CHARLOTTE, 28217-5593
- Web
- https://www.cbdmd.com/
- Phone
- +1 7044453060
- Auditors
- Cherry Bekaert LLP
Upcoming Events for YCBD
Q1 2025 cbdMD Inc Earnings Release
Similar to YCBD
FAQ
As of Today at 19:49 UTC, shares in cbdMD are trading at $0.47. This share price information is delayed by 15 minutes.
Shares in cbdMD last closed at $0.47 and the price had moved by -57.73% over the past 365 days. In terms of relative price strength the cbdMD share price has underperformed the S&P500 Index by -67.98% over the past year.
The overall consensus recommendation for cbdMD is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morecbdMD does not currently pay a dividend.
cbdMD does not currently pay a dividend.
cbdMD does not currently pay a dividend.
To buy shares in cbdMD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.47, shares in cbdMD had a market capitalisation of $1.75m.
Here are the trading details for cbdMD:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: YCBD
Based on an overall assessment of its quality, value and momentum cbdMD is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in cbdMD is $2.00. That is 330.11% above the last closing price of $0.47.
Analysts covering cbdMD currently have a consensus Earnings Per Share (EPS) forecast of -$2.63 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like cbdMD. Over the past six months, its share price has underperformed the S&P500 Index by -53.24%.
As of the last closing price of $0.47, shares in cbdMD were trading -34.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The cbdMD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
cbdMD's management team is headed by:
- Martin Sumichrast - CHM
- Raymond Coffman - CCE
- T. Ronan Kennedy - CFO
- Francisco Mangual - SVP
- David Johnson - SVP
- Matthew Coapman - CMO
- Sibyl Swift - VPR
- Lance Blundell - GCN
- Peter Ghiloni - IND
- William Raines - IND
- Bakari Sellers - IND
- Scott Stephen - IND